{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:54:13Z","timestamp":1784138053135,"version":"3.55.0"},"reference-count":30,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v102.1088","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T06:45:40Z","timestamp":1643265940000},"page":"adv00677","source":"Crossref","is-referenced-by-count":28,"title":["Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience"],"prefix":"10.2340","volume":"102","author":[{"given":"Danielle","family":"Rogner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilo","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"16904","doi-asserted-by":"crossref","unstructured":"Ring J, Zink A, Arents BWM, Seitz IA, Mensing U, Schielein MC, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol 2019; 33: 1331-1340.","DOI":"10.1111\/jdv.15634"},{"key":"16905","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15634","DOI":"10.1111\/jdv.15634"},{"key":"16906","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878.","DOI":"10.1111\/jdv.14888"},{"key":"16907","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14888","DOI":"10.1111\/jdv.14888"},{"key":"16908","doi-asserted-by":"crossref","unstructured":"Hajar T, Hanifin JM, Gontijo JRV. New and developing therapies for atopic dermatitis. An Bras Dermatol 2018; 93: 104-107.","DOI":"10.1590\/abd1806-4841.20187682"},{"key":"16909","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1590\/abd1806-4841.20187682","DOI":"10.1590\/abd1806-4841.20187682"},{"key":"16910","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Rosmarin D, Bieber T, Simpson EL, Bagel J, Worm M, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol 2019; 181: 196-197.","DOI":"10.1111\/bjd.17703"},{"key":"16911","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.17703","DOI":"10.1111\/bjd.17703"},{"key":"16912","doi-asserted-by":"crossref","unstructured":"Lauffer F, Ring J. Target-oriented therapy: emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs 2016; 21: 81-89.","DOI":"10.1517\/14728214.2016.1146681"},{"key":"16913","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1517\/14728214.2016.1146681","DOI":"10.1517\/14728214.2016.1146681"},{"key":"16914","doi-asserted-by":"crossref","unstructured":"Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol 2020; 21: 119-131.","DOI":"10.1007\/s40257-019-00478-y"},{"key":"16915","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-019-00478-y","DOI":"10.1007\/s40257-019-00478-y"},{"key":"16916","doi-asserted-by":"crossref","unstructured":"Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol 2018; 78: S53-S62.","DOI":"10.1016\/j.jaad.2017.12.019"},{"key":"16917","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2017.12.019","DOI":"10.1016\/j.jaad.2017.12.019"},{"key":"16918","doi-asserted-by":"crossref","unstructured":"Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat 2020 Nov 22. [Epub ahad of print].","DOI":"10.1080\/09546634.2020.1839008"},{"key":"16919","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2020.1839008","DOI":"10.1080\/09546634.2020.1839008"},{"key":"16920","doi-asserted-by":"crossref","unstructured":"Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 1333-1343.","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"16921","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"16922","doi-asserted-by":"crossref","unstructured":"Averitt AJ, Weng C, Ryan P, Perotte A. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med 2020; 3: 67.","DOI":"10.1038\/s41746-020-0277-8"},{"key":"16923","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41746-020-0277-8","DOI":"10.1038\/s41746-020-0277-8"},{"key":"16924","doi-asserted-by":"crossref","unstructured":"Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.","DOI":"10.1034\/j.1600-0625.2001.100102.x"},{"key":"16925","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1034\/j.1600-0625.2001.100102.x","DOI":"10.1034\/j.1600-0625.2001.100102.x"},{"key":"16926","doi-asserted-by":"crossref","unstructured":"Singh RK, Finlay AY. Dermatology Life Quality Index use in skin disease guidelines and registries worldwide. J Eur Acad Dermatol Venereol 2020; 34: e822-e824.","DOI":"10.1111\/jdv.16701"},{"key":"16927","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16701","DOI":"10.1111\/jdv.16701"},{"key":"16928","doi-asserted-by":"crossref","unstructured":"Oranje AP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol 2011; 41: 149-155.","DOI":"10.1159\/000323308"},{"key":"16929","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000323308","DOI":"10.1159\/000323308"},{"key":"16930","doi-asserted-by":"crossref","unstructured":"Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92: 497-501.","DOI":"10.2340\/00015555-1265"},{"key":"16931","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1265","DOI":"10.2340\/00015555-1265"},{"key":"16932","doi-asserted-by":"crossref","unstructured":"Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255.","DOI":"10.1111\/bjd.18898"},{"key":"16933","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18898","DOI":"10.1111\/bjd.18898"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1088\/3241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1088\/3246","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1088\/3241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T17:18:13Z","timestamp":1655918293000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/1088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.1088","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,22]]}}}